Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial
Authors:
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 261, 145-152
Abstract
No abstract availableKeywords
Funding Information
- Stanley Medical Research Institute (10T-1401)
This publication has 38 references indexed in Scilit:
- Celecoxib augmentation of escitalopram in treatment-resistant bipolar depression and the effects on Quinolinic AcidNeurology, Psychiatry and Brain Research, 2019
- Revisiting inflammation in bipolar disorderPharmacology Biochemistry and Behavior, 2019
- Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatmentJournal of Psychiatric Research, 2018
- Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double‐blind, placebo‐controlled trialBipolar Disorders, 2015
- The Immunology of Bipolar DisorderNeuroimmunomodulation, 2014
- Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled studyJournal of Affective Disorders, 2012
- Predominant recurrence polarity among 928 adult international bipolar I disorder patientsActa Psychiatrica Scandinavica, 2011
- Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trialDepression and Anxiety, 2009
- A Multidimensional Tool to Quantify Treatment Resistance in DepressionThe Journal of Clinical Psychiatry, 2009
- Clinical and therapeutic implications of predominant polarity in bipolar disorderJournal of Affective Disorders, 2006